Coherent Sells Over 7500 Excimer Lasers for Refractive Surgery

Article

Coherent is unique amongst laser manufacturers in the breadth of our excimer laser product portfolio and the depth of our experience in building products for both Laser-Assisted In Situ Keratomileusis (LASIK) and other refractive techniques.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
A Canadian flag in front of a mountain range. Concept image for Alcon Clareon Panoptix Pro intraocular lens IOL launch and approval in Canada. Image credit: ©toptop54 from pixabay - Canva.com

Clareon Panoptix Pro IOL (Alcon) approved in Canada

Jordana Joy
July 9th 2025
Article

The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Precautionary class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, issued

Precautionary class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, issued

Kassi Filkins
July 8th 2025
Article

A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A man in a bed takes a pill. Concept image for oral therapy, danegaptide non proliferative diabetic retinopathy medication. Image credit: ©Jelena – stock.adobe.com

Breye Therapeutics completes phase 1B trial of danegaptide oral therapy for diabetic retinopathy

Lynda Charters
July 8th 2025
Article

Investigators reported the oral therapy was well-tolerated in trials for early treatment of non-proliferative diabetic retinopathy and associated oedema

A photo showing Sebastian Rausch, PhD, clinical development manager for investigational technologies (left) and Roland Rocholz, PhD, technology and innovation manager. Image courtesy of Heidelberg Engineering

Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration

Jordana Joy
July 7th 2025
Article

The imaging innovation project is named after the company's cofounder Gerhard Zinser, PhD

© 2025 MJH Life Sciences

All rights reserved.